Silymarin inhibits the lipogenic pathway and reduces worsening of non-alcoholic fatty liver disease (NAFLD) in mice.
Sign Up to like & getrecommendations! Published in 2022 at "Archives of physiology and biochemistry"
DOI: 10.1080/13813455.2022.2138445
Abstract: CONTEXT The role of silymarin in hepatic lipid dysfunction and its possible mechanisms of action were investigated. OBJECTIVE To evaluate the effects of silymarin on hepatic and metabolic profiles in mice fed with 30% fructose… read more here.
Keywords: silymarin; silymarin inhibits; reduces worsening; lipogenic pathway ... See more keywords
Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt‐dependent lipogenic pathway
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.17435
Abstract: Mounting evidence indicates that hepatic de novo lipogenesis is a common abnormality in non‐alcoholic fatty liver disease (NAFLD) patients. We investigated whether a selective COX‐2 inhibitor, celecoxib, alleviates hepatic steatosis by targeting an Akt‐driven lipogenic… read more here.
Keywords: celecoxib; lipogenic pathway; novo lipogenesis; lipogenesis ... See more keywords